Lipella Pharmaceuticals Inc. LIPO
0.00 USD 0.00 (+0.00%)
At closeNov 9, 2026, 4:00 PM EST
1.80 +1.80 +359,920.00%
After hours · Nov 9, 4:00 PM ET
0.0327 Day range 0.058
0.0002 52-week range 0.545
- YTD
- -99.72%
- 1 year
- -99.86%
News
globenewswire.com Lipella Pharmaceuticals Inc. Files Voluntary Petitions for Relief Under Chapter 11 PITTSBURGH, March 30, 2026 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (“Lipella” or the “Company”), a clinical-stage biotechnology company, announced today that it filed a voluntary petition…
defenseworld.net Lipella Pharmaceuticals (NASDAQ:LIPO) Trading Down 14.8% – Here’s What Happened Lipella Pharmaceuticals Inc. (NASDAQ: LIPO - Get Free Report)'s stock price dropped 14.8% on Tuesday. The stock traded as low as $0.3410 and last traded at $0.3410. Approximately 22,645 shares traded…
defenseworld.net Lipella Pharmaceuticals (NASDAQ:LIPO) Stock Price Up 4.2% – Still a Buy? Lipella Pharmaceuticals Inc. (NASDAQ: LIPO - Get Free Report) shares rose 4.2% on Monday. The stock traded as high as $0.4532 and last traded at $0.4532. Approximately 5,172 shares changed hands…
globenewswire.com Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting PITTSBURGH, June 25, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for…
globenewswire.com Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market PITTSBURGH, June 20, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for…
globenewswire.com Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology PITTSBURGH, June 17, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for…
prismmediawire.com Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development Supports late-stage development and scalable manufacturing for LP-310, a non-steroidal oral rinse therapy for Oral Lichen Planus, a condition with no approved treatments PITTSBURGH, June 4, 2025 –…
globenewswire.com Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development PITTSBURGH, June 04, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
prismmediawire.com Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting Statistically significant safety and efficacy data from 0.25 mg and 0.50 mg cohorts to be presented Presentation scheduled for Thursday, May 15, 2025, at 11:36 a.m. PT PITTSBURGH, May 15, 2025 –…
globenewswire.com Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting Statistically significant safety and efficacy data from 0.25 mg and 0.50 mg cohorts to be presented Presentation scheduled for Thursday, May 15, 2025, at 11:36 a.m. PT PITTSBURGH, May 15, 2025 (GLOBE…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
globenewswire.com Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine” Joint meeting to be held in Las Vegas, May 14-17 Presentation will be delivered by Dr. Alessandro Villa of Miami Cancer Institute Topline study results demonstrate clinically meaningful improvements…
prismmediawire.com Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine” Listen: PITTSBURGH, April 23, 2025 – PRISM MediaWire – Lipella Pharmaceuticals Inc.
prismmediawire.com Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025 Listen: PITTSBURGH, April 22, 2025 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage biotechnology company addressing…
globenewswire.com Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025 Second Cohort Results Highlight Efficacy Across All Key Measures and Reinforce Safety of Twice-Daily Oral Rinse Phase 2a Study Now Fully Enrolled Across All Three Dose Cohorts Advancing Toward Phase…
prismmediawire.com Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus Topline Results Expected Q2 2025 Listen: PITTSBURGH, April 08, 2025 – PRISM MediaWire – Lipella Pharmaceuticals Inc.
globenewswire.com Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus PITTSBURGH, April 08, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative…
prismmediawire.com Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast Episode titled “From Medicine to Biotech Innovation” now available PITTSBURGH, March 31, 2025 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the…
globenewswire.com Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast PITTSBURGH, March 31, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage biotechnology company addressing serious…
globenewswire.com Spartan Capital Securities, LLC Announces Key February Transactions New York, NY, March 07, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a full-service investment banking firm, is pleased to announce a series of strategic transactions completed in…
globenewswire.com Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $3,788,000 Private Placement New York, NY, March 04, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the successful completion of a $3,788,000 private placement…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Dow Edges Higher; US Weekly Jobless Claims Increase 
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com Dow Edges Lower; Ventyx Biosciences Shares Plummet
- benzinga.com Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
- benzinga.com Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump
- benzinga.com Nasdaq Gains 1%; McDonald's Posts Downbeat Results
- benzinga.com Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com Why Natera Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
- benzinga.com Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expected fourth-quarter earnings and issued 2024 guidance.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session - benzinga.com Why Harley-Davidson Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers
- benzinga.com Why Microsoft Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Gainers ReShape Lifesciences Inc. (NASDAQ: RSLS) shares surged 62.8% to $0.3348 in pre-market trading after gaining over 6% on Tuesday. ReShape Lifesciences recently announced pricing of $3.0 million…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday saw 132 companies set new 52-week lows.
- benzinga.com Why Startek Shares Are Trading Higher By 29%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers SuperCom Ltd. (NASDAQ: SPCB) shares jumped 89% to $0.6805, after falling 13% on Monday.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday's session, 406 companies made new 52-week lows.
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com Why Titan Machinery Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) shares jumped 40.2% to $2.5109 after the company announced the successful completion of a Phase 2A clinical trial evaluating the safety and…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com Stocks That Hit 52-Week Lows On Friday Friday saw 23 companies set new 52-week lows.
- benzinga.com Why KNOT Offshore Partners Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers BigBear.ai Holdings, Inc. (NYSE: BBAI) shares jumped 239% to $2.8715 after the company announced it has been awarded a multiple award $900 million Indefinite Delivery/Indefinite Quantity…
- benzinga.com Why Akerna Shares Are Trading Higher By 97%; Here Are 20 Stocks Moving Premarket Gainers Akerna Corp. (NASDAQ: KERN) rose 97.4% to $1.91 in pre-market trading after the company reported the sale of 365 Cannabis for $2.8 million.